Part 2 of “Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions” is now out in the The Journal of Nuclear Medicine – JNM.

Building on Part 1, this publication explores the key dynamics shaping the future of radiopharmaceutical therapy, from theranostic integration and novel α-emitting isotopes to clinical development, manufacturing readiness, supply security and evolving reimbursement frameworks.

📊 Once again, MEDraysintell provided the industry data and analysis supporting the paper’s market and investment trends.

Our sincere thanks to the authors: Catello Somma, Richard Zimmermann, Germo Gericke, and Ken Herrmann. We are always glad to see our market intelligence contribute to a deeper understanding of the opportunities and challenges shaping the field.

👉 Read the article : https://lnkd.in/e5eEsevw

#Radiopharmaceuticals #NuclearMedicine #RLT #HealthcareInnovation #MEDraysintell #Theranostics

Image Source : Brechin V, Mario N., MEDraysintell Nuclear Medicine Series 2025.